CAR T-cell expansion, DOR, and PFS by age group in ZUMA-1 phase 2 patients. (A) Peak levels (left) and AUC (days 0-28; right) of anti-CD19 CAR T cells per µL blood in patients ≥65 and <65 years of age. Phase 2 patients (n = 101) are shown. CAR T-cell levels were not available for 3 patients. (B) DOR among responders ≥65 and <65 years of age. (C) PFS in patients ≥65 and <65 years of age. AUC, area under the curve; CI, confidence interval; NE, not estimable.